Quantcast
Home > Quotes > ACRS

Aclaris Therapeutics, Inc. Common Stock (ACRS) Quote & Summary Data

ACRS 
$20.03
*  
0.39
1.99%
Get ACRS Alerts
*Delayed - data as of May 18, 2018  -  Find a broker to begin trading ACRS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
51
Today's High / Low
$ 20.12 / $ 19.49
Share Volume
198,116
50 Day Avg. Daily Volume
254,175
Previous Close
$ 19.64
52 Week High / Low
$ 30.08 / $ 16.011
Market Cap
619,047,240
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.91
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.53

Intraday Chart

Shares Traded

Share Volume:
198,116
50 Day Avg. Daily Volume:
254,175

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.91

Trading Range

The current last sale of $20.03 is 25.10% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 20.12 $ 30.08
 Low: $ 19.49 $ 16.011

Company Description (as filed with the SEC)

We are a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology and immunology. Our lead product, ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution that has been approved by the U.S. Food and Drug Administration, or FDA, as a prescription treatment for raised seborrheic keratosis, or SK, a common non-malignant skin tumor. The FDA approved our New Drug Application, or NDA, for ESKATA for the treatment of raised SKs in December 2017, making ESKATA the first drug approved by the FDA for the treatment of raised SKs. We also submitted a Marketing Authorization Application, or MAA, for ESKATA in the European Union in July 2017.  ... More ...  

Risk Grade

Where does ACRS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 19.77
Open Date:
May 18, 2018
Close Price:
$ 20.03
Close Date:
May 18, 2018

Consensus Recommendation

Analyst Info